Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

PM Society announces 2023 Digital Award winners

PM Society announces 2023 Digital Award winners

Other Gold winners were Alliance Pharma, Bayer, CALM, Haleon, Kite Pharma, a Gilead Company, Kyowa Kirin, LEO Pharma, the RCN Foundation, Novartis, Santen, Takeda UK and UCB.

US government announces first ten drugs subject to Medicare pricing negotiations

US government announces first ten drugs subject to Medicare pricing negotiations The list includes Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Novartis' Entresto (valsartan/sacubitril), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and

Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis

Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis Sandoz, a Novartis division, has announced that its biosimilar Tyruko (natalizumab-sztn) has been approved by the US Food and Drug Administration (FDA) to treat adults with relapsing forms of multiple

Merck shares positive late-stage results for Welireg in advanced kidney cancer

Merck shares positive late-stage results for Welireg in advanced kidney cancer According to data from a pre-specified interim analysis of the study, Welireg showed a statistically significant and clinically meaningful improvement in progression-free survival compared to Novartis’ Afinitor (everolimus).

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives Novartis has shared positive top-line results from two late-stage studies evaluating its Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib, in patients with chronic spontaneous urticaria (CSU) whose symptoms are ... Novartis’ remibrutinib works

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

PMHub

Add my company
Onyx Health

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....